BioStock: Curasight gets green light from EMA in phase II prostate cancer trial
The partnership deal closed with Curium last year marks the most important milestone for Curasight to date. Now, the European Medicines Agency (EMA) has approved the clinical trial application for the phase II study with uTRACE in prostate cancer.
– The acceptance illustrates the strong progress being made in developing uTRACE, CEO Ulrich Krasilnikoff comments.
Read the full article at biostock.se:
This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se